This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in ...

Merck & Co., Inc. (NYSE: MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck Foundation First Ladies Initiative - MFFLI to discuss 2026 strategy and share programs’ impact to Train Healthcare ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:00 PM ESTCompany ParticipantsEliav Barr - Chief Medical ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.

We came across a bullish thesis on Merck & Co., Inc. on Darius Dark Investing’s Substack. In this article, we will summarize ...

Dr. Rasha Kelej discusses with Nigeria First Lady their joint programs to build healthcare and media capacity and Support ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...